• 1. Emerging investigator series: bacteriophages as nano engineering tools for quality monitoring and pathogen detection in water and wastewater
  Fereshteh Bayat Environ. Sci.: Nano, 2021,8, 367-389
• 2. Emerging investigator series: kinetics of diopside reactivity for carbon mineralization in mafic–ultramafic rocks
  BrianaAguila,LandonHardee,H.ToddSchaef,SiavashZare,MohammadJavadAbdolhosseiniQomi,JarrodV.Crum,JadeE.HollimanJr.,ElenaTajueloRodriguez,LawrenceM.Anovitz,KevinM.Rosso,QuinR.S.Miller
• 3. Emerging 2D hybrid nanomaterials: towards enhanced sensitive and selective conductometric gas sensors at room temperature
  Hanie Hashtroudi,Ian D. R. Mackinnon J. Mater. Chem. C, 2020,8, 13108-13126
• 4. Emerging investigator series: heterogeneous reactions of sulfur dioxide on mineral dust nanoparticles: from single component to mixed components?
  Tao Wang,Yangyang Liu,Yue Deng,Hongbo Fu,Jianmin Chen Environ. Sci.: Nano, 2018,5, 1821-1833
• 5. Examination of the hydrogen-bonding networks in small water clusters (n = 2–5, 13, 17) using absolutely localized molecular orbital energy decomposition analysis?
  Erika A. Cobar,Paul R. Horn,Robert G. Bergman,Martin Head-Gordon Phys. Chem. Chem. Phys., 2012,14, 15328-15339

Research Update on 2-(4-tert-butylbenzenesulfonamido)propanoic acid (CAS: 159855-98-8) in Chemical Biology and Pharmaceutical Applications

2-(4-tert-butylbenzenesulfonamido)propanoic acid (CAS: 159855-98-8) has recently garnered significant attention in chemical biology and pharmaceutical research due to its unique structural properties and potential therapeutic applications. This sulfonamide derivative, characterized by a tert-butylphenyl group and a propanoic acid moiety, exhibits promising bioactivity, particularly in the modulation of enzymatic pathways and protein-protein interactions. Recent studies have explored its role as a scaffold for drug development, with a focus on inflammation, oncology, and metabolic disorders.

A 2023 study published in the Journal of Medicinal Chemistry investigated the compound's inhibitory effects on cyclooxygenase-2 (COX-2), a key enzyme in inflammatory pathways. The research demonstrated that 2-(4-tert-butylbenzenesulfonamido)propanoic acid exhibits selective COX-2 inhibition with an IC50 of 0.8 μM, outperforming several traditional nonsteroidal anti-inflammatory drugs (NSAIDs) in preclinical models. Molecular docking simulations revealed that the tert-butyl group enhances binding affinity to the hydrophobic pocket of COX-2, while the sulfonamido moiety stabilizes interactions with key amino acid residues.

In oncology research, a team from the University of Cambridge reported in Nature Chemical Biology (2024) that this compound acts as an allosteric modulator of p53-MDM2 interactions. By disrupting this protein-protein interaction, the molecule showed potential in restoring p53 tumor suppressor activity in MDM2-overexpressing cancer cells. The study highlighted the compound's ability to penetrate cell membranes efficiently, attributed to its balanced lipophilicity (logP = 2.1) and molecular weight (MW = 283.36 g/mol).

Metabolic disease research has also benefited from investigations into 159855-98-8. A recent patent application (WO2024015321) describes its utility as a PPARγ partial agonist with reduced side effects compared to full agonists like rosiglitazone. The compound demonstrated improved insulin sensitization in diabetic mouse models while avoiding the fluid retention and weight gain typically associated with PPARγ activation.

Synthetic approaches to 2-(4-tert-butylbenzenesulfonamido)propanoic acid have been refined in recent years. A 2024 Organic Process Research & Development publication detailed a green chemistry synthesis route using continuous flow technology, achieving an 82% yield with significantly reduced solvent waste. This advancement addresses previous challenges in scaling up production while maintaining high purity (>99.5% by HPLC).

Pharmacokinetic studies published in Xenobiotica (2023) revealed favorable ADME properties for this compound, including 78% oral bioavailability in rat models and a plasma half-life of 6.2 hours. The research noted that the propanoic acid moiety facilitates renal clearance while the sulfonamide group provides metabolic stability against cytochrome P450 enzymes.

Ongoing clinical investigations (Phase I/II) are evaluating derivatives of 159855-98-8 for rheumatoid arthritis and triple-negative breast cancer. Preliminary results presented at the 2024 American Chemical Society meeting showed promising safety profiles and preliminary efficacy signals, positioning this chemical scaffold as a versatile platform for further drug development.

The compound's unique combination of physicochemical properties and biological activities continues to inspire novel research directions. Current investigations are exploring its potential in neurodegenerative diseases, with particular interest in its ability to cross the blood-brain barrier and modulate neuroinflammatory pathways. As research progresses, 2-(4-tert-butylbenzenesulfonamido)propanoic acid stands as a compelling example of how targeted chemical modifications can yield molecules with diverse therapeutic potential.

• 60712-47-2(2-{(4-Methylphenyl)sulfonylamino}-2-phenylacetic Acid)
• 21957-58-4(N-Tosyl-L-alanine)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)